ForeFront is a collaborative research group in Australia dedicated to the study of frontotemporal dementia (FTD) and motor neurone disease (MND).
FTD and MND are a group of disorders identified by distinct clinical signs and symptoms, and/or specific brain pathologies. These disorders are generally rapidly progressing, cause behavioural, language or motor deficits (often in combination), and together are a leading cause of dementia, particularly in people under 65 years of age.
ForeFront is an amalgamate of two government funded research groups:
Frontotemporal dementia and motor neurodegenerative syndromes
This National Health and Medical Research Council (NHMRC) program brings together a team of internationally recognised leaders in clinical, pathological and biological research on FTD and motor neurodegenerative syndromes. Individually these team leaders, along with their research staff, have made significant advances in these diseases, and this program will unify their efforts and focus on translating findings into better clinical information and intervention studies.
Memory node of the ARC Centre of Excellence in Cognition and its Disorders This program investigates the cognitive systems and brain structures underlying various forms of memory, including autobiographical memory, episodic memory and semantic memory. The program uses experimental neuropsychological methods, as well as structural and functional brain imaging in patients with progressive brain pathologies such as frontotemporal dementia. Despite sustained research interest spanning 50 years, the cognitive and neural architecture of episodic and semantic memory systems and the factors that affect their optimal functions are still not fully understood.
In Australia alone, 250,000 people are affected by bipolar disorder. Current treatments are highly variable for the severe and debilitating psychiatric condition and the specific genetic causes have remained largely obscure. Bipolar disorder is most commonly treated with lithium, but this is only effective for 30% of patients. Unlocking the genetic code of bipolar disorder and using pharmacogenomics studies to […]